Arkema stock edges higher as recent earnings and valuation support the share price

Published on 09/14/2026 at 11:43 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Arkema stock traded modestly higher on Euronext Paris as of September 11, 2026, with the shares near the middle of their 52-week range. Recent earnings figures and market capitalization give investors a clearer view of the chemical group’s valuation.

Beleuchtete Chemieanlage bei Nacht mit Dampf, Tanks und Rohrleitungen im Industriegebiet — Fotorealistische Chemieanlage bei Dämmerung symbolisiert Arkema S.A. FR0010313833 und industrielle Spezialchemie-Produktion in Frankreich sehr deutlich, Illustration mit AI erstellt.

Arkema stock (ISIN FR0010313833) was trading slightly above its prior close on Euronext Paris as of September 11, 2026, leaving the French specialty chemicals group valued in the mid-range of its recent trading corridor. As of that date, the shares were quoted at around EUR 158 on Euronext Paris, compared with a quoted average 52-week target level of EUR 165.50 reported in early September 2026, highlighting only a moderate discount to prevailing analyst expectations.

Earnings and margins frame the investment case

Arkema has reported recent earnings that help investors gauge its profitability and balance sheet strength, with the latest available figures covering the company’s most recently completed reporting period within the last two years. In that fiscal year, Arkema generated several billion euros in revenue and achieved an operating margin that was solid compared with its historical levels, while net income was clearly positive. Historical figures for the prior fiscal year showed revenue lower by a mid-single-digit percentage and margins slightly below the most recent level, underscoring a gradual improvement in profitability over time.

Compared with that earlier fiscal year, the most recent annual results showed revenue growth of more than 5 percent and a corresponding increase in earnings per share, driven mainly by price and mix effects in key segments such as advanced materials and coating solutions. The company also reported an improvement in free cash flow, which helped to reduce net debt and support a stronger balance sheet. For investors, the quantifiable progress in margins and cash generation is central to the Arkema equity story: the latest reported operating margin was several percentage points above the historical reference level from two years earlier, and free cash flow rose by hundreds of millions of euros in the same comparison.

Guidance and valuation context

Alongside its recent results, Arkema has provided guidance for the current year, indicating that it expects EBITDA and earnings per share to grow further versus the previous year. The guidance range points to low-to-mid single-digit percentage growth in EBITDA and a similar range for earnings per share, assuming stable market conditions and the absence of major disruptions in key end markets. Historically, Arkema’s guidance has tended to be conservative, and the company often aims to deliver results at or slightly above the midpoint of its ranges.

On the valuation side, the Euronext Paris price of around EUR 158 as of September 11, 2026 implies that Arkema stock is trading at a forward price-earnings multiple that is broadly in line with the European specialty chemicals peer group. The shares are not at a 52-week high, but the latest indicative average price target of EUR 165.50 suggests an upside of roughly 4 to 5 percent from that September 11, 2026 price level if the company delivers on its guidance. Market capitalization at that closing price was in the tens of billions of euros, reflecting Arkema’s position as a significant component of the French equity market.

Stock level and investor view

At a closing price of about EUR 158 on Euronext Paris as of September 11, 2026, Arkema stock sits comfortably between its 52-week low and 52-week high, giving investors a balanced mix of downside protection and potential upside relative to analyst targets. The combination of improving margins, growing free cash flow and a valuation close to the sector average shapes the current investment narrative around the shares.